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ABSTRACT
G-quadruplexes (G4s) are non-canonical nucleic
acids secondary structures that form within guanine-
rich strands of regulatory genomic regions. G4s have
been extensively described in the human genome,
especially in telomeres and oncogene promoters; in
recent years the presence of G4s in viruses has at-
tracted increasing interest. Indeed, G4s have been
reported in several viruses, including those involved
in recent epidemics, such as the Zika and Ebola
viruses. Viral G4s are usually located in regulatory
regions of the genome and implicated in the control
of key viral processes; in some cases, they have been
involved also in viral latency. In this context, G4 lig-
ands have been developed and tested both as tools
to study the complexity of G4-mediated mechanisms
in the viral life cycle, and as therapeutic agents. In
general, G4 ligands showed promising antiviral activ-
ity, with G4-mediated mechanisms of action both at
the genome and transcript level. This review aims to
provide an updated close-up of the literature on G4s
in viruses. The current state of the art of G4 ligands
in antiviral research is also reported, with particular
focus on the structural and physicochemical require-
ments for optimal biological activity. The achieve-
ments and the to-dos in the field are discussed.
INTRODUCTION
G-quadruplexes (G4s) are nucleic acids secondary struc-
tures that can form within DNA (1) or RNA (2) guanine
(G)-rich strands, when two or more G-tetrads stack on top
of each other and coordinate monovalent cations, such as
K+ and Na+. Each tetrad is composed of four G residues
that are linked by the sugar–phosphate backbone and con-
nected through Hoogsteen-type hydrogen bonds. G4s are
highly polymorphic structures whose topology can be influ-
enced by variations in strand stoichiometry and polarity, as
well as by the nature and length of loops and their location
in the sequence. G4s can fold intramolecularly from a sin-
gle G-rich strand, or intermolecularly through dimerization
or tetramerization of separate filaments: research of biolog-
ically relevant G4s has mainly focused on monomolecular
G4s (3,4); however, intermolecular G4s are gaining increas-
ing attention (5–7). Strands orientation defines the paral-
lel, antiparallel or mixed topology of G4s, which is directly
correlated to the conformational state, anti or syn, of the
glycosidic bond between the G base and the sugar (1). The
anti conformation characterizes a parallel folding, while an-
tiparallel G4s are found to adopt both syn and anti orien-
tations (8) (Figure 1). While RNAG4s are mostly locked in
a parallel conformation due to the 2′-hydroxyl group in the
sugarwhich exclusively allows the anti orientation (2),DNA
G4s are in principle characterized by higher topological di-
versity, even though the majority of DNAG4s examined so
far adopt the parallel topology.
Computational analysis using different algorithms (9,10)
indicated that 300 000 and up to around 3 000 000 poten-
tial G4-forming sequences may form in the human genome,
correlated with specific gene functions (11). These data have
been corroborated by ‘G4-seq’ high-throughput sequenc-
ing method, which identified about 700 000 G4s (12). How-
ever, mapping of G4s in chromatin by G4 ChIP-sequencing
with an anti-G4 antibody (13) or footprinting (14) retrieved
only about 10 000 G4s in highly transcribed regulatory
nucleosome-depleted chromatin regions. These data indi-
cate that G4s are mostly suppressed in chromatin and that,
in turn, they may influence the occupancy and positioning
of nucleosomes.
In general, G4 sequences are non-randomly distributed
but mainly clustered in pivotal genomic regions, namely
telomeres, gene promoters and DNA replication origins
(15). Moreover, putative G4-forming sequences have been
found in coding and non-coding regions of the human tran-
scriptome, i.e. open reading frames and untranslated re-
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Figure 1. The G-quadruplex structure. (A) Chemical structure (left) and
schematic illustration (right) of a G-tetrad, composed of four guanines
linked together through Hoogsteen H-bonds (red dashed lines); M+ rep-
resents the monovalent cation coordinated at the center of the tetrad. (B)
Different topologies of intramolecular G4 structures.
gions (UTRs), and in the telomeric repeat-containing RNA
(2).This evidence suggests that G4s are likely involved in the
regulation of different biological pathways such as replica-
tion, transcription, translation and genome instability.
In the past years, the resolution of G4 structures (16–
18) and the employment of novel visualization approaches
(19–21) helped researchers to validate the previous compu-
tational predictions, disclosing new aspects of the multi-
faceted G4s world, e.g. the effective occurrence of G4s
within patient-derived cancer tissues (22) or the key role
in the pathogenesis of two incurable neurodegenerative dis-
eases, amyotrophic lateral sclerosis and frontotemporal de-
mentia (23). Indeed, the presence of G4s in the human
genome and their potential in diseases modulation have
been extensively investigated, resulting in many good and
exhaustive reviews focused onG4 structures (1,8,24,25) and
their biological role, particularly in telomeres (26–29) and
oncogene promoters (30–35).
G-QUADRUPLEXES IN VIRUSES: PRESENCE AND
FUNCTION
Besides humans, putative G4-forming sequences have been
found in other mammalian genomes (36), yeasts (37), pro-
tozoa (38), bacteria (39,40) and viruses, therefore implicat-
ing G4s in many human infectious diseases. One review has
been published in 2015 on the possible role of G4s in the
antigenic variation systems of bacteria and protozoa and
silencing of two viruses (41). The possible role of G4s in
viruses and the use of G4-forming oligonucleotides as an-
tiviral agents have been discussed in 2014 (42).
Figure 2. Schematic representation of the viral life cycle. The virus rec-
ognizes and binds the host cell surface receptors (step 1) to enter the cell
(step 2). After penetration, the viral genome is uncoated (step 3) and its
DNA or RNA nature determines where and how the genome is replicated
(step 4): most DNA viruses replicate in the cell nucleus, while the major-
ity of RNA viruses replicate in the cytoplasm of infected cells. After viral
mRNA production, viral proteins are expressed in the cytoplasm (steps 5–
6). The newly synthesized viral genomes and proteins are then assembled
into new virions (step 7), which are released outside the cell (step 8).
Since the number of reports describing the presence of
G4s in virus genomes has boomed in the past 2 years and
treatment with several G4 ligands has shown potentially in-
teresting therapeutic activity, we here aim at presenting, or-
ganizing and discussing an up-to-date close-up of the litera-
ture onG4s in viruses and the classes of molecules that have
shown antiviral activity by viral G4 targeting. In particular,
we first focus on the presence and proposed function of G4s
in virus genomes. Next, we present the classes of G4 ligands
that have reported successful antiviral activity, with special
emphasis on the structural and physicochemical properties
that characterize the viral G4/G4 ligand interaction. A gen-
eral simplified virus life cycle is schematically depicted in
Figure 2; a summary of the viruses in which G4s have been
reported and of the corresponding G4s is shown in Figure
3. Since the use of G4-forming oligonucleotides as antiviral
agents has been more recently addressed by Musumeci et
al. (43,44), this topic has not been considered in the present
review.
Human immunodeficiency virus
The human immunodeficiency virus (HIV) is the etiolog-
ical agent of the acquired immune deficiency syndrome
(AIDS), which to date affects more than 35 million people
worldwide. Albeit the current anti-retroviral therapy keeps
the disease progression under control, people still die from
HIV-related causes; thereby it is necessary to find alter-
native and effective antiviral targets. The HIV belongs to
the Retroviridae family; the single-stranded RNA genome
is processed by the viral retrotranscriptase and the newly
formed double-stranded DNA is integrated into the host
cell chromosomes to form the proviral genome, from which
viral mRNAs and new genomes are transcribed.
The research of G4s in the HIV-1 genome has been quite
productive, concerning not only the two RNA viral genome
copies, but also the integrated proviral genome, specifically
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Figure 3. Summary of G4s reported in viral genomes. For each virus the following information is shown: virion structure and dimension, genome size and
organization; schematic representation of the G4 (red dots) location in the viral genomes or in the mRNA andG4 binding proteins; number of G4s assessed
through bioinformatics analysis, according to the corresponding references; G4 ligands reported to date to display antiviral effect and corresponding
references.
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in the long terminal promoter (LTR) region (45–47) and in
the nef coding region (48), as properly reviewed by Metifiot
et al. (42).
Briefly, the LTR promoter is characterized by a highly
conserved G-rich sequence in the U3 region, correspond-
ing to Sp1 and NF-B binding sites, where three mutually
exclusive G4 structures can form, i.e. LTR-II, LTR-III and
LTR-IV (46). LTR-IV is a parallel G4 with a bulge at its 3′-
end, as ascertained by nuclear magnetic resonance (NMR)
characterization (49). LTR-III and LTR-IV exert opposite
effects on LTR promoter activity, which is silenced when
LTR-III is folded and enhanced by LTR-IV stabilization
(49). In addition, the LTR G4 region is under the control
of two nuclear proteins: nucleolin, which upon binding in-
creases LTRG4 stability and thus silences transcription (50)
and the human ribonucleoprotein (hnRNP) A2/B1, which
unwinds the LTR region, decreasing its promoter activity
(51): these data suggest that the balance betweenG4s acts as
a regulatory mechanism in HIV-1 promoter activity. Inter-
estingly, G4-forming sequences are present in the LTR pro-
moter of all primate lentiviruses and display binding sites
for transcription factors that are related to G4 regulation
(52,53), supporting a role for G4s as crucial control ele-
ments for viral transcription, conserved throughout evolu-
tion (54).
G4s were also evidenced in the U3 region of the HIV-
1 RNA genome, where multiple highly stable parallel G4s
can form (55). RNA sequences can dimerize through an in-
termolecular G4 interaction (56), suggesting that the U3 re-
gion could represent an additional point of contact between
the two viral genome copies. Additionally, such RNA G4s
likely contribute to the observed increased genetic recombi-
nation rate in the U3 (57).
Nef, a viral accessory protein, is an essential factor in
proviral DNA synthesis (58) and in the establishment of a
persistent state of infection (59). Its coding region is located
at the 3′-end of the viral genome and partially overlaps with
the 3′-LTR. Three G4 sequences have been identified in the
most conserved region of the gene (48).
G-rich sequences able to form G4s were reported in
the HIV central DNA flap overlapping positive-strand and
were found to protect the pre-integrated genome from nu-
clease degradation (60).
Stabilization of HIV G4s by small molecules showed an-
tiviral effects at different levels: G4 ligand binding to DNA
LTR G4s decreased viral transcription, while binding to
RNA LTR G4s inhibited the reverse transcription process,
leading in both cases to strong antiviral effects (46,55,61).
G4 ligand-mediated stabilization of the nef G4s induced
nef-dependent antiviral activity (48). Very recently, G4 sta-
bilizing agents were also employed in cells infected with la-
tent HIV-1, where their activity resulted in a strong antivi-
ral effect, especially in combination with a DNA repair in-
hibitor, revealing new aspects of HIV-1 latent infection (62).
The specific molecules that were used as anti-HIV-1
agents are discussed in the ‘Antiviral G4 ligands’ section of
this review.
Herpesviruses
Herpesviridae is a large family of viruses with long lin-
ear double-stranded DNA genomes. Among the nine her-
pesvirus species that can infect humans, at least five are ex-
tremely widespread, i.e. herpes simplex virus 1 and 2 (HSV-
1 and HSV-2), varicella zoster virus, Epstein–Barr virus
(EBV) and cytomegalovirus, which cause orolabial and gen-
ital herpes (63), chickenpox and shingles (64), mononucleo-
sis (65) and some cancers (66). More than 90% of adults
have been infected with at least one of these (63). Her-
pesviruses also tend to display latent, recurring infections,
with the virus remaining in some part of the infected organ-
ism and typically maintaining its genome as extrachromo-
somal nuclear episome (67).
Recent genome-wide bioinformatics analysis revealed an
impressively high density of putative G4-forming sequences
in all herpesvirus species (68). Indeed, the presence of G4s
has been experimentally reported for HSV-1, EBV, Kaposi’s
sarcoma associated herpesvirus (KSHV) and human her-
pesvirus 6 (HHV-6).
HSV-1 establishes life-long persistent infections with a
viral lifecycle that involves latency and reactivation/lytic
replication. More than half of the world population suffers
from HSV infections, the outcome of which may become
severe in immunocompromised patients. Anti-HSV-1 ther-
apy can be very effective; however, the emergence of drug-
resistant viral strains urges the discovery of anti-herpetic
drugs with innovative mechanisms of action. The HSV-1
genome, characterized by 68% GC-content, was found to
contain numerous and highly stable G4-forming sequences
that are mainly located in the repeated regions (69). These
HSV-1 G4s, visualized through a G4-specific antibody in
infected cells at different time points post-infections, were
shown to form in a virus cycle-dependent fashion: viral G4s
form massively in the cell nucleus during viral replication,
and localize in different cell compartments according to the
viral genome movements (70).
EBV is associated not only with the well-known infec-
tious mononucleosis, but also with a wider spectrum of
illnesses, including several lymphoid malignancies. Stud-
ies on the presence and role of G4s in EBV proved that
the genome maintenance protein EBV-encoded nuclear
antigen-1 (EBNA1) stimulates viral DNA replication by re-
cruiting the cellular origin replication complex through an
interaction with RNA G4s (71). The EBNA1 mRNA itself
is rich in G clusters able to fold into parallel G4s, which
behave as cis-acting regulators of viral mRNA translation,
producing ribosome dissociation. G4s in EBNA1 mRNA
have been shown to modulate the endogenous presenta-
tion of EBNA1-specific CD8+ T-cell epitopes, which are
involved in persistent infections (72). The cellular protein
nucleolin counteracts this mechanism by interacting with
EBNA1mRNAG4s and thus downregulating EBNA1 pro-
tein expression and antigen presentation (73,74). G4s can
also be observed in the mRNAs of other genome main-
tenance proteins that are known to regulate their self-
synthesis, suggesting that G4s are exploited as structural
regulatory elements by the virus (75).
KSHV is the etiological agent of all forms ofKaposi’s sar-
coma and other numerous lymphoproliferative disorders,
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which mostly concern AIDS patients, and at the moment,
no treatments for the lytic or latent infections are avail-
able (76). The KSHV genome is organized in a 137 kb long
unique region, flanked by the terminal repeats, which are
rich in G residues and able to form stable G4s, both in the
forward and reverse strands (77).
HHV-6 is a ubiquitous virus that infects almost 100% of
the human population. The diseases associated with HHV-
6 include the febrile illness roseola infantum, also known
as the sixth childhood eruptive disease (78). Reactivation of
HHV-6 in immunosuppressed individuals is associated with
adverse clinical outcomes, comprising life-threatening en-
cephalitis or graft rejection in transplant patients (79). The
HHV-6 genome presents telomeric regions at its termini,
which can integrate into the telomeres of human chromo-
somes: integration is considered one possible mode of la-
tency (80). Since telomeres can fold into G4s, these struc-
tures may be involved in the mechanism of HHV-6 integra-
tion. Indeed, stabilization of telomeric G4s by a G4 ligand
inhibited HHV-6 chromosomal integration (81).
Stabilization of herpesvirus G4s by G4 ligands led to an-
tiviral activity. InHSV-1, inhibition ofDNA replication and
reduction of late viral transcripts were observed (69,82). In
EBV, a G4 ligand inhibited EBNA1-dependent stimulation
of viral DNA replication (71) and EBNA1 synthesis (75).
In contrast, another G4 ligand reduced nucleolin binding
to EBNA1 mRNA (75), which in turn resulted in enhanced
EBNA1 synthesis and antigen presentation (73,74).
Treatment of latently infected cells with G4 stabilizing
compounds proved to negatively regulate viral replication,
leading to a reduction in the KSHV genome copies (77).
G4 ligands used against herpesviruses are discussed in the
‘Antiviral G4 ligands’ section of this review.
Other viruses
DNA viruses. The human papillomavirus (HPV) is a
double-stranded DNA virus that can cause skin and genital
warts and some types of cancer. Its genome displays several
G-rich sequences: stable G4s form in only eight out of 120
identified HPV types; however, the G4-forming HPVs in-
clude some of the most high risk HPV types, responsible
for the majority of cases of cervical cancer (83,84).
The Hepatitis B virus (HBV) is a partially double-
strandedDNA virus, the best knownmember of theHepad-
naviridae family. It causes the hepatitis B disease, whichmay
lead to cirrhosis and hepatocellular carcinoma. A single pu-
tative G4-forming sequence was discovered in the promoter
region of the preS2/S gene in HBV genotype B and was
found to fold into an intramolecular hybrid G4 structure.
Surprisingly, the G4 acted as a positive regulator of HBV
transcription, as revealed by luciferase reporter assays (85).
Adeno-associated viruses (AAV) are single-stranded
DNA viruses of the Parvoviridae family. AAV are not cur-
rently linked to human diseases and have been used as de-
livery vectors for gene therapy. A recent study reported the
presence ofG4s in theAAVgenome. TheDNAbinding pro-
tein nucleophosmin (NPM1), which is known to enhance
AAV infectivity, directly interacts withG4s: 18 putative G4s
were identified, located within the inverted terminal repeat
region (86).
RNA viruses. Amongst RNA viruses, G4 putative se-
quences have been identified in three positive and single-
stranded ones, namely the severe acute respiratory syn-
drome coronavirus (SARS-CoV), the Hepatitis C virus
(HCV) and the Zika virus (ZIKV).
The SARS-CoV belongs to the family of Coronaviri-
dae; its genome is about 29.7 Kb, which is one of the
largest among RNA viruses. It has been identified after
a massive outbreak in 2003 and is considered one of the
most pathogenic coronaviruses in humans. Within the non-
structural protein 3, the so-called SARS unique domain
(SUD), which plays an essential role in viral replication and
transcription, was found to preferentially bind G4-forming
oligonucleotides (87,88). These may be found in the 3′-non-
translated regions of mRNAs coding for host-cell proteins
involved in apoptosis or signal transduction; therefore, it
has been proposed that SUD/G4 interaction may be in-
volved in controlling the host cell’s response to the viral in-
fection.
The HCV belongs to the Flaviviridae family; it can cause
both acute and chronic hepatitis, possibly leading to cirrho-
sis and liver cancer. Bioinformatics and biophysical analysis
demonstrated the existence of two highly conserved G4 se-
quences in the C gene of HCV (89).
The ZIKV is also included in the family of Flaviviridae.
It is transmitted to humans by mosquito bites; while in
an adult it may cause mild symptoms or even be symp-
tomless, it may be devastating in a pregnant woman as it
causes microcephaly in the unborn child. Several G4 se-
quences were discovered in the positive strand of the ZIKV
genome: 7 of these are conserved within more than 50 fla-
vivirus genomes, suggesting an important role in the life cy-
cle of these viruses. Furthermore, ZIKV presents an addi-
tional G4 in the unique 3′-UTR region, crucial for initial
viral replication of the negative-sense strand (90).
Finally, G4s have been investigated in the Ebola virus
(EBOV) and Marburg virus (MARV), two negative and
single-stranded RNA viruses belonging to the Filoviridae
family. These are deadly pathogens that cause haemorrhagic
fever in humans and primates (91). The presence of G4 se-
quences in the negative strand of EBOV and MARV was
assessed by a fluorescent probe (92).
BothZIKVandEBOLVwent throughmassive outbreaks
in the past three years, which makes them two of the most
dangerous agents of viral epidemics of the current decade.
In Figure 3, all the viruses in which G4s have been inves-
tigated are displayed. The stabilizing G4 ligands tested in
some of these viruses are thoroughly described in the sec-
tion below.
ANTIVIRAL G4 LIGANDS: DEVELOPMENT, ANTIVI-
RAL ACTIVITY AND MECHANISM
In the past few years much effort has been directed toward
the design of small molecules able to target G4s, leading
to very promising potential therapeutics, especially against
cancer. Several updated reviews describe the use of G4
ligands that target telomeres and oncogenes to treat can-
cer (8,34,93–95).
Despite the considerable achievements in antiviral re-
search, viral infections still represent a major global threat
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for human health, causing significant morbidity and mor-
tality. The recurrent onset of drug-resistant pathogens, com-
bined with the fact that the majority of viruses still lack a
specific vaccine, urges the development of novel therapeu-
tic approaches for the management of viral diseases. To this
end, G4 ligands provide both compounds with an innova-
tivemechanismof action in antiviral treatment and valuable
tools to better understand virus mechanisms.
In the section below G4 ligands reported to exert antivi-
ral activity have been grouped based on the chemical nature
of their core. A description of their discovery, general G4
binding activity and biological effects in cells is initially pro-
vided. Antiviral properties, activity and selectivity are then
discussed.
BRACO-19
The N,N’-(9-((4-(dimethylamino)phenyl)amino)acridine-
3,6-diyl)bis(3-(pyrrolidin-1-yl)propan-amide), labeled
BRACO-19 (B19) (1, Figure 4), is to date one of the
most studied G4 ligands. It is the outcome of a complex
and thorough medicinal chemistry investigation that
started with the introduction of an acridine moiety as a
new chromophore in the research of G4 binders. Read
and colleagues demonstrated that the acridine core was
more active than the previously developed anthraquinone
core (96,97), because of the presence of a nitrogen atom
in the heterocyclic scaffold that could be protonated
at physiological conditions. As a result, the electron
deficiency in the chromophore was increased, with conse-
quent enhancement of the G4 interaction (98). In-depth
structure-activity relationship (SAR) analysis supported
by molecular modeling techniques next led to the devel-
opment of bi- and tri-substituted derivatives (99,100).
These classes of compounds are characterized by a central
planar pharmacophore that binds G-tetrads through –
interactions (Figure 5A). Additionally, two side chains
functionalized with a tertiary amine moiety are needed to
interact with the grooves: the amine group is crucial for
activity since it is protonated at physiological pH, while it
disrupts the G4 when substituted with bulky residues (101).
The 3,6,9-trisubstituted acridines emerged as the most
potent compounds among all the possible regioisomeric
series that have been evaluated: they proved to act as G4-
mediated telomerase inhibitors. B19 showed telomerase
inhibition at nanomolar concentration, with higher affinity
for G4 with respect to duplex DNA, and lower cytotoxicity
when compared to first generation acridines. It induced
long-term growth arrest and replicative senescence in the
21NT breast carcinoma cell line and was the first G4 ligand
to prove anticancer activity in vivo, against human tumor
xenograft models (102,103).
The use of B19 in a viral environment was first ana-
lyzed in EBV, to investigate the functional and biochemi-
cal characteristics of EBNA1. Results showed that B19 sta-
bilized the viral RNA G4 and, during infection, was able
to reduce EBV genome copy numbers in Raji cells. It was
also found to induce modest reduction of transcription lev-
els of EBNA2 and EBNA3A and inhibition of EBNA1-
dependent DNA replication. These data indicate that G4-
interacting molecules can block functions of EBNA1 that
are critical for viral DNA replication (71).
In the LTR promoter region of the HIV-1 proviral
genome, B19 was able to significantly stabilize the naturally
occurring G4s, LTR-II and LTR-III, and to induce an addi-
tional G4, LTR-IV. In the presence of increasing concentra-
tion of B19, LTR promoter activity was decreased of almost
70% with respect to the untreated control, while no activity
was detected in a mutated sequence unable to fold into G4s
(46). These results confirmed a G4-mediated mechanism of
action. The anti-HIV-1 activity of B19 (IC50 < 7.9 M)was
tested in various cell lines, against different viral strains and
was demonstrated to be G4 mediated. Since G4 structures
also formed in the pre-integration viral RNA (55), a dual
mode of action both at the pre- and post-integration level
was proposed (Figure 6). B19 antiviral activity was tested
and confirmed in latent HIV-1 infected cells, where the acri-
dine was able to reduce the viral titer to undetectable level,
also in long-term treatment (62).
B19 exerted its G4 stabilizing activity also in the HSV-1
genome, where multiple G4s can form. Treatment with B19
led to a significant antiviral effect (IC50 = 8 M), with re-
duction in viralDNA synthesis and late proteins production
(69).
Moreover, B19 was used in HHV-6A infected cells to
evaluate the ability of G4 ligands to impair viral integra-
tion in the telomeric region, through stabilization of telom-
eric G4s. Interestingly, in telomerase expressing cell lines,
the frequency of chromosomal integration was reduced up
to 50% upon treatment. However, effects of G4 ligands on
HHV-6 replication and gene expression are yet to be discov-
ered (81).
Recently, B19 was employed in a luciferase reporter assay
to analyze the role of G4s in HBV, where it enhanced pro-
moter activity, suggesting a positive regulatory role of G4s
in HBV transcription (85).
Despite its good solubility in aqueous solutions and
strong G4 binding, poor permeability across biological
barriers, which characterizes most G4 ligands, restrains
B19 pharmacological application (104). Nonetheless, B19
is still considered a reference compound in G4 research.
TMPyP4
The cationic porphyrin compound 5,10,15,20-tetrakis-(N-
methyl-4-pyridyl)porphine (TMPyP4, 2, Figure 4) was pro-
posed as G4 binder because of its suitable physical proper-
ties, such asmolecular size, planar core, positive charges and
hydrophobicity, favorable for stacking with the G tetrads
(105) (Figure 5B). Biophysical analysis demonstrated that
TMPyP4was actually able to stack and stabilize both paral-
lel and antiparallel G4s, withmild selectivity for quadruplex
over duplex DNA (95). Since then, it has been widely em-
ployed as a tool to studyG4s, especially because of the avail-
ability of a negative control compound, TMPyP2 (3, Fig-
ure 4), which is a structural isomer withN-methyl-2-pyridyl
residues on the porphine core. Intriguingly, TMPyP2 is ster-
ically hindered from external stacking on the G4 with re-
spect toTMPyP4, producing no biological effects (106,107).
In biological assays, TMPyP4 was shown to inhibit hu-
man telomerase (IC50 = 6.5 ± 1.4 M) (108) and downreg-
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Figure 4. Chemical structures of reported G4 ligands with antiviral activity.
Figure 5. Solved crystal structures for three of the compounds discussed in the text. (B) Crystal structure of the complex between B19 and the bimolecular
human telomeric G4 (PDB ID: 3CE5): each quadruplex contains three planar stacked G-tetrads with the molecule stacking directly onto the 3′ end quartet
(136). (B) Crystal structure of the complex between TMPyP4 and the bimolecular human telomeric G4 (PDB ID: 2HRI). The compound binds by stacking
onto the TTA nucleotides, as part of the external loop or at the 5′ region of the stacked quadruplex (105). (C) Crystal structure of the complex between
PhenDC3 and the human c-myc-promoter G4 (PDB ID: 2MGN). The ligand establishes an optimal interaction with the top G-tetrad, while the two
N-methyl groups are positioned above the grooves and have minimal contact with the tetraplex (132).
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Figure 6. Proposed antiviral mechanism of the G4 ligand B19. In HIV-
1 infected cell, B19 exerts a dual mechanism of action: it recognizes and
stabilizes the DNA G4s in the 5′-LTR within the proviral genome in the
cell nucleus, and it binds to the RNAG4s in the 5′-LTR and 3′-LTR of the
viral genome in the cytoplasm: such interactions result in the inhibition of
viral direct and reverse transcription.
ulate the proto-oncogene c-myc expression as well as several
c-myc-regulated genes containing G4-forming sequences.
Such modulation resulted in in vivo antitumor activity in
different models where the porphyrin was able to decrease
tumor growth and prolong survival (109).
In viruses, TMPyP4 was shown to stabilize G4s in the
HIV-1 nef coding region and to induce their formation
within the double-helix conformation. Interestingly, in the
TZM-bl reporter cell line, which supports nef-dependent
HIV-1 replication, the porphyrin inhibited viral infectivity
in a dose-dependent manner (48). In addition, TMPyP4
administration was able to block viral replication in two
different Jurkat-derived T-cell lines with established HIV-
1 latency. Bambara’s research group demonstrated that the
antiviral activity was coupled with an increased rate of
apoptosis/deathwhen compared to untreated cells, and that
this effect was enhanced by association with DNA damage
repair inhibitors (62).
In HCV, TMPyP4 was found to stabilize RNA G4s and
inhibit HCV C gene expression through a G4-mediated
mechanism of action confirmed by an enhanced green flu-
orescent protein reporter gene system. In addition, in an
infectious HCV culture system, administration of the por-
phyrin led to a dose-dependent decrease of viral RNA levels
(89).
TMPyP4was also employed to investigate the role of G4s
in EBOV L gene. It exerted high stabilization of the tar-
get G4 RNA in circular dichroism and RNA stop assays.
More importantly, after treatment with increasing concen-
trations of the compound, transcription of the L gene was
gradually reduced. To confirm target selectivity, a mutant
non-G4-forming sequence was used as a negative control,
where TMPyP4 did not produce significant inhibition of
transcription. In addition, the porphyrin was found to in-
hibit replication of EBOV mini-genome, a cell-based ap-
proach that uses firefly luciferase as reporter protein and
thus can be used as an efficient antiviral screening system
(91).
It is worth noting that the low selectivity of TMPyP4 to-
wards G4 structures versus duplex DNA (110) may suggest
the antiviral activity to be ascribed to multiple mechanisms
of action, limiting its biological and clinical application.
Perylenes and naphthalene diimides
Perylenes represent a well-known family of G4 ligands, con-
taining a differently substituted, large fused aromatic ring
system: they are characterized by a hydrophobic heptacyclic
central core, which is responsible for the binding to G quar-
tets through – interactions, and by up to four proto-
nated side chains. Accurate SAR studies on this scaffold
pointed out two crucial features for G4 binding: the ba-
sicity of the system, which prevents the compound from
self-aggregation, and the distance between the aromatic
central core and the quaternarized nitrogen residue in the
side chain, which modulates ligand solubility and affects
G4 recognition. The cationic amino moieties in the lateral
substituents are thought to regulate specificity for G4 ver-
sus duplex DNA (111). PIPER, N,N’-bis[2-(1-piperidino)-
ethyl]-3,4,9,10-perylenetetracarboxylic diimide (4, Figure
4) is the lead compound of this class; it was shown to in-
duce and stabilize G4 structures in telomeres (112), leading
to telomere shortening, reduction of cell proliferation and
tumorigenicity, and senescence (113).
In the effort to improve the physicochemical properties
of the perylene scaffold, progressive surface reduction led
to the more promising class of naphthalene diimide (NDI)
derivatives. Indeed, it was demonstrated that the dimen-
sions of the planar core modulate the ability of this class
of compounds to recognize different DNA conformations.
In particular, in the cyclic condensed system at least four
rings are required to efficiently target G4s (114). In addi-
tion, the NDI planar core can accommodate up to four
side chains to enhance G4 affinity. These compounds were
found to inhibit telomerase activity in the low micromo-
lar range and to produce short-term cell growth inhibition
againstMCF-7 andA549 cancer cell lines (115). To improve
DNA G4 alkylating properties, further modifications were
introduced on theNDI scaffold, which include quinoneme-
thides precursors (116,117). These ligands revealed both re-
versible and irreversible binding properties toward telom-
eric DNA, with promising duplex versus quadruplex selec-
tivity (118), and were found to impair the growth of dif-
ferent telomerase-positive cancer cell lines following telom-
erase activity inhibition (119–121). Crystallographic analy-
ses of various NDI–telomere complexes provided a turning
point for rational optimization of this class of compounds
(122,123). Neidle et al. reported that the tested ligands pro-
moted a parallel G4 topology, forming a 1:1 complex with
the oligonucleotide. This stoichiometry resulted from the
combination of binding site affinity and direct groove inter-
actions that are highly influenced by the protonated moiety
in the side chains, which interacts with DNA phosphates in
the grooves.
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Despite their high molecular weight, NDIs are highly
versatile structures, suitable for further medicinal chem-
istrymodifications to improve their pharmacological profile
(124,125).
In the antiviral field, PIPER induced and stabilized G4
structures in the nef coding region of the HIV-1 genome
(48). However, the best results were obtained with core-
extended NDI derivatives (c-exNDIs, 5, Figure 4). This
series of compounds, endowed with exceptional solubility
properties, has been obtained by fusing the NDI core with a
1,4-dihydroquinoxaline heterocycle. Interestingly, the newly
developed ligands displayed greater in vitro binding and sta-
bilization activity on viral HIV-1 LTRG4s than the human
telomeric sequence, used as a cellular reference G4. Most
importantly, the c-exNDIs exhibited very promising antivi-
ral activity in the low nanomolar range (IC50 < 25 nM)
against different strains of HIV-1, with very low cytotoxi-
city, yielding a wide and encouraging therapeutic window.
The G4-related mechanism of action was proved combin-
ing time-related antiviral and reporter assays, using a non-
G4-forming LTR-mutant sequence as control. It is reason-
able that the higher antiviral activity depends on the selec-
tivity toward the viral G4s, as, during the infection, LTR
and telomeric G4s are likely the most abundant species in
the cell (61).
The most active c-exNDI was also analyzed in HSV-1
infection. In vitro CD and Taq-polymerase stop assays in-
dicated that the compound was able to bind and stabilize
various G4-forming sequences of the HSV-1 genome. Mass
spectrometry competition analysis revealed a stronger pref-
erence for HIV-1 G4s over HSV-1, but generally, viral G4s
were preferentially bound, when compared to the telomeric
G4. Indeed, c-exNDI showed remarkable antiviral activity
(IC50 = 18.3 ± 1.4 nM). The anti-herpetic effect was as-
cribed to inhibition of viral DNA replication, as gathered
by time-of-addition assay and flow cytometry analysis us-
ing acyclovir as reference compound (82). Since c-exNDI
selectivity towards HSV-1 G4s in vitro resulted to be good
but not outstanding, the marked anti-HSV-1 activity was
likely due also to the massive presence of viral G4s in the
cell nucleus, which was demonstrated to occur during HSV-
1 replication (70).
Pyridostatin
Pyridostatin (PDS, 6, Figure 4) has been rationally designed
on the structural features shared by known G4-binding lig-
ands, as it comprises a potentially planar electron-rich aro-
matic surface and the ability to participate in hydrogen
bonding.Moreover, the rotatable bonds provide a flexibility
degree, whichmakes PDS capable to adapt to the dynamism
of G4s. PDS strongly stabilized telomeric G4 with no effect
on double-strandedDNA: as a result, the shelterin complex
integrity was altered, triggering aDNA-damage response at
telomeres (126). Numerous modifications have been intro-
duced in the PDS scaffold to further explore the role of this
class in anticancer therapy. Indeed, the obtained analogues
showed remarkable growth-inhibitory effects in cancer cell
lines and a complete arrest after long-term exposure to the
drug. These results emphasize the high potential of these
compounds to fine-tune their biological activity (127,128).
In antiviral research, PDS has been used to study the role
of G4s in EBV EBNA1 mRNA, where it enhanced the sta-
bility of the G4-forming sequence, decreasing EBNA1 syn-
thesis level in a concentration-dependent fashion, both in
vitro and in vivo. As a consequence, EBV-infected cells re-
sulted less efficiently recognized by virus-specific T cells, al-
beit the mechanism of action still needs to be clarified (75).
In HBV, PDS was used to unravel the positive regulatory
role of G4s within the preS2/S gene promoter (85).
A PDS analogue, namely PDP (7, Figure 4), was em-
ployed in HCV G4 research, along with TMPyP4. The
PDP-induced stabilization of G4 structures located in the
HCVRNA downregulated C gene expression. In vivo, PDP
inhibited intracellular replication of different HCV geno-
types through a confirmedG4-relatedmechanism of action,
resulting in antiviral activity in the low micromolar range
(89).
Bisquinolinium derivatives
Bisquinolinium compounds are characterized by an aro-
matic nucleus substituted with two protonated quino-
line moieties. The first reported compounds present a
dicarboxamide-pyridine or -triazine ring as central core:
the most promising of these ligands have shown to increase
G4 stability in telomeres, with great selectivity over duplex
DNA (129). These compounds are able to adopt an in-
tramolecular syn-syn H-bond, which was proposed to be
critical for G4 recognition, likely because the consequent
rigidity of the compound promotes G-quartet overlap. On
these bases, the central core was expanded without dis-
rupting the H-bonds, leading to a new disubstituted-1,10-
phenanthroline series that displays exceptional selectivity
for G4s (130), due to the crescent-like shape which prevents
such compounds to intercalate with duplex DNA (Figure
5C) (131,132). PhenDC3 (8, Figure 4), the best represen-
tative of this class, is a potent telomeric G4 ligand able to
reduce telomerase processivity (133).
PhenDC3was used inKSHV to evaluate its potential role
in inhibiting latent viral replication. The ligand was found
to elicit a stress response in infected BCBL-1 cells and to
stall the replication machinery both in the leading and lag-
ging strands of the KSHV genome. Furthermore, treatment
with PhenDC3 resulted in the dramatic reduction (60%) of
episome copy number, with no effect on cell growth and pro-
liferation. These data represent the first use of G4 ligands in
targeting latent viral infections (77).
PhenDC3 was also used in EBV, where it prevented bind-
ing of nucleolin to EBNA1mRNAG4 and increased the en-
dogenous EBNA1 levels in EBV-infected B cells and in cells
derived from a nasopharyngeal carcinoma. These results in-
dicate that the nucleolin–EBNA1 mRNA interaction can
also be targeted by antiviral G4-ligands (74).
A summary of G4 ligands and the viruses against which
they have been tested is reported in Figure 3.
DISCUSSION AND FUTURE PERSPECTIVES
In the last decades, research on the role of G4s in the hu-
man genome has been quite challenging and promising,
leading to the awareness that these high-order structures
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play key regulatory roles in biological pathways such as
transcription, replication, translation and telomere main-
tenance. The development of G4 binders with encourag-
ing anti-cancer activity has prompted researchers to iden-
tify new ways to exploit G4 structures in human diseases,
e.g. viral infections.
Because G4s are present both in cell and virus genomes,
the challenge in developing antiviral G4 ligands reasonably
consists in overcoming selectivity toward viral versus cel-
lular G4s. A major limitation of the so far described G4
ligands is their large flat aromatic core that stacks on the
G tetrad, which reduces the chances to discriminate among
differentG4s.Moreover, they are generally characterized by
high-molecular weights and protonated side chains, which
are necessary for loops and grooves interaction, but, on the
other hand, may affect cellular uptake. Indeed, because of
the low selectivity profile and poor drug-like properties, no
G4 ligand has advanced beyond Phase II in the drug dis-
covery pathway. Quarfloxin, a fluoroquinolone derivative
compound developed by Hurley’s research group (134), is
to date the only G4 ligand that has reached Phase II clin-
ical trials but was withdrawn due to bioavailability related
problems (35). However, several data presented in the liter-
ature indicate that, in general, a certain degree of selectivity
is achievable towards the viral G4 of interest in compari-
son to the telomeric G4, i.e. the most abundant cellular G4
(135). In the case of HIV-1 G4s and c-exNDI compounds,
the higher affinity towards the viral structure is likely caused
by the extension of theNDI core and thus by the interaction
with the viral G4 loop region, which is unique for this G4
(61). In general, loop and groove regions characterize each
G4 and thus are amenable for selective recognition. Struc-
tural studies on cellular G4/G4 ligand complexes indicated
that most G4-binding molecules interact with G4s through
quasi-external stacking, in which the heteroaromatic chro-
mophore of the small molecules is – stacked onto the
face of an external G-quartet (136) (Figure 5) and onto the
side chains positioned in the G4 grooves (94). It is therefore
conceivable that the reported antiviral activity ofG4 ligands
is mediated by an increased interaction, hence affinity, with
the groove/loop moiety of the viral G4s. To date, only one
viral G4 structure has been resolved through NMR spec-
troscopy (49), therefore future NMR and crystallographic
resolutions of viral G4s and G4/G4 ligand complexes are
necessary to define the viral G4s architecture. This could
help researchers identifying possible unique G4 structures
which could lead to the design and development of selec-
tive molecules.
In other cases, G4 ligands did not show significant selec-
tivity for the viral versus telomeric G4s, and theG4s present
in oncogene promoters were usually strongly bound by the
tested compounds (82). Nonetheless, the data so far pre-
sented on the antiviral use of G4 ligands have shown in gen-
eral very promising activity against a wide range of virus
species. One possible explanation is that the amount of the
viral G4s in the infected cells largely surpasses that of the
cellular G4s (70). Indeed, usually cells are exploited to func-
tion as factories in the production of new viral genomes
that are eventually assembled into new mature virus par-
ticles (See Figure 2 for the viral infection cycle). It is thus
conceivable that the viral G4s become largely more abun-
dant than the cellular G4s during virus replication. At least
in one case this eventuality has been demonstrated: in HSV-
1 there is a sharp increase in the number of viral G4s dur-
ing viral DNA replication (70). Combining the abundance
of G4s per genome and the number of new genomes, the
amount of viral G4s could outstand that of cellular G4s
by several logs per cell. In addition, the so far identified vi-
ral G4s are usually key regulatory elements of the virus life
cycle and their stabilization/unfolding by G4 ligands can
likely explain the resulting massive virus inhibition. If this
behaviour is demonstrated also in other viruses, it would be
possible to exploit G4 ligands that are not strictly selective
for the viral G4s. This scenario would highly and rapidly ex-
pand the research and pharmacological application of G4
ligands as antiviral agents.
A further point to be addressed is the necessity to stan-
dardize methods to study the antiviral activity of the G4
ligands. One starting point should be the detection of the
inhibitory activity of the ligand on the virus life cycle. If an
effect is obtained, further investigation on the mechanism
of action has to be performed. In this regard, the time of
addition method (137) can be of assistance as it indicates
the last viral step at which the compound is active and it
thus narrows the possible molecular targets. However, be-
cause of the complexity and uniqueness of each virus, the
investigation of the target and mechanism of action at the
molecular level may not be straightforward. For example,
PDS inhibited EBNA1 synthesis in vitro but not in cells,
while PhenDC3 in cells led to the exact opposite effect, i.e.
enhanced EBNA1 synthesis (74,75). It is likely that multi-
ple G4-mediated mechanisms are involved in the observed
outcomes.
Finally, targeting G4s in the viral genomes leads to the
exciting possibility of affecting viruses that undergo latency.
These viruses, such as HIV, the herpes and papilloma virus
families, comprise an initial acute infection and a subse-
quent latent infection. The latter is characterized by the
maintenance of the virus genome in the human host for the
entire life of the host. The latent virus may reactivate from
time to time to produce newmature virus. Current therapies
that normally target viral proteins fail to remove the latent
virus, i.e. the virus genome, from its host. Selectively tar-
geting the viral genome in a G4-mediated approach would
allow removing not only the replicating virus but also the
latent one, therefore eradicating so far incurable infective
agents.
In this picture it is worth considering the virus-induced
manipulation of host chromatin. In recent years, studies
about the role of chromatin in viral infections showed dy-
namic virus–host chromatin interactions and chromatin
machinery modulation by virus encoded proteins (138). For
example, the HSV-1 epigenetic regulation of viral chro-
matin by viral gene products plays a key role in determin-
ing whether the virus develops a lytic or latent infection
(139). Considering the recent evidences reported byHa¨nsel-
Hertsch et al. that G4 formation reflects the suppressive role
of heterochromatin and that it occurs only in highly tran-
scribed regulatory nucleosome-depleted chromatin regions
(13), it would be interesting to understand how the virus
and its G4s affect and could be affected by such a complex
mechanism.
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To conclude, all the data reported in this review indicate
that: i) G4 structures are crucial elements in the regulation
of viruses’ life cycle, both in lytic and latent states; ii) G4 lig-
ands efficiently act as antiviral agents. This should encour-
age researchers to continue investigating on G4-binding
small molecules: as a matter of fact, albeit quarfloxin clini-
cal evaluation did not progress, its success in Phase I clinical
trial, i.e. optimal toxicity profile (35), suggests that improve-
ments of G4 ligand pharmacological profiles will very likely
lead to concrete clinical applications of these compounds.
Therefore, research in the next future will need to improve
i) the understanding of G4 activity and regulation at the vi-
ral level, ii) the selectivity ofG4 ligands toward the viral ver-
sus cellular G4s, iii) the drug-like properties of the antiviral
G4 ligands to be employed in in vivo studies.
G4-mediated antiviral drugs may represent a significant
turning point in the management of viral infections, espe-
cially for people who cannot access immunization, like im-
munocompromised patients or elderly people. In addition,
the G4-mediated antiviral effects reported in latent infec-
tions (62) may pave the way for cutting-edge therapeutic
approaches in the treatment of human fatal malignancies
related to latent viruses, such as AIDS, herpes- and HPV-
related cancer.
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